369 related articles for article (PubMed ID: 31471142)
1. Autotaxin and chronic inflammatory diseases.
Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
[TBL] [Abstract][Full Text] [Related]
2. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin in Pathophysiology and Pulmonary Fibrosis.
Ninou I; Magkrioti C; Aidinis V
Front Med (Lausanne); 2018; 5():180. PubMed ID: 29951481
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
Trovato FM; Zia R; Napoli S; Wolfer K; Huang X; Morgan PE; Husbyn H; Elgosbi M; Lucangeli M; Miquel R; Wilson I; Heaton ND; Heneghan MA; Auzinger G; Antoniades CG; Wendon JA; Patel VC; Coen M; Triantafyllou E; McPhail MJ
Hepatology; 2021 Aug; 74(2):907-925. PubMed ID: 33908067
[TBL] [Abstract][Full Text] [Related]
5. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes.
Sevastou I; Kaffe E; Mouratis MA; Aidinis V
Biochim Biophys Acta; 2013 Jan; 1831(1):42-60. PubMed ID: 22867755
[TBL] [Abstract][Full Text] [Related]
6. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.
Magkrioti C; Oikonomou N; Kaffe E; Mouratis MA; Xylourgidis N; Barbayianni I; Megadoukas P; Harokopos V; Valavanis C; Chun J; Kosma A; Stathopoulos GT; Bouros E; Bouros D; Syrigos K; Aidinis V
Cancer Res; 2018 Jul; 78(13):3634-3644. PubMed ID: 29724718
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer.
Meng G; Tang X; Yang Z; Zhao Y; Curtis JM; McMullen TPW; Brindley DN
FASEB J; 2019 Feb; 33(2):1899-1910. PubMed ID: 30192654
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte autotaxin expression promotes liver fibrosis and cancer.
Kaffe E; Katsifa A; Xylourgidis N; Ninou I; Zannikou M; Harokopos V; Foka P; Dimitriadis A; Evangelou K; Moulas AN; Georgopoulou U; Gorgoulis VG; Dalekos GN; Aidinis V
Hepatology; 2017 Apr; 65(4):1369-1383. PubMed ID: 27981605
[TBL] [Abstract][Full Text] [Related]
9. Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate.
Benesch MG; Zhao YY; Curtis JM; McMullen TP; Brindley DN
J Lipid Res; 2015 Jun; 56(6):1134-44. PubMed ID: 25896349
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
11. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis.
Rancoule C; Dusaulcy R; Tréguer K; Grès S; Attané C; Saulnier-Blache JS
Biochimie; 2014 Jan; 96():140-3. PubMed ID: 23639740
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
13. Signalling by lysophosphatidate and its health implications.
Hemmings DG; Brindley DN
Essays Biochem; 2020 Sep; 64(3):547-563. PubMed ID: 32451553
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
[TBL] [Abstract][Full Text] [Related]
16. The Expression Regulation and Biological Function of Autotaxin.
Zhang X; Li M; Yin N; Zhang J
Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
[TBL] [Abstract][Full Text] [Related]
17. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells.
Nikitopoulou I; Fanidis D; Ntatsoulis K; Moulos P; Mpekoulis G; Evangelidou M; Vassiliou AG; Dimakopoulou V; Jahaj E; Tsipilis S; Orfanos SE; Dimopoulou I; Angelakis E; Akinosoglou K; Vassilaki N; Tzouvelekis A; Kotanidou A; Aidinis V
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576169
[TBL] [Abstract][Full Text] [Related]
18. Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.
Alioli C; Demesmay L; Peyruchaud O; Machuca-Gayet I
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408784
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease.
Jose A; Kienesberger PC
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502491
[TBL] [Abstract][Full Text] [Related]
20. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
